A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects ≤ 17 Years of Age With Cerebral Adrenoleukodystrophy (CALD)

Project: Research project

Description

A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects ≤ 17 Years of Age With Cerebral Adrenoleukodystrophy (CALD)
StatusActive
Effective start/end date2/1/191/31/24

Funding

  • Bluebird Bio, Inc.

Fingerprint

Adrenoleukodystrophy
Busulfan
Pharmaceutical Preparations
fludarabine